UnevenBackpack

I have one more question :)

Has MAPS done any research on HPPD? There are some horror stories on reddit (r/HPPD) which are difficult to read and I’m sure scare people off. Wouldn’t it take only 1 of these to happen during a clinical trial to set us back decades (yet again)?

The screening of participants seems very strict for lost studies, and rightly so (history of mental illness, hereditary factors, certain personality traits, even physiological ones), however there seems to be a serious lack of understanding regarding the ostensibly random nature of, dare I say, permanent, HPPD in some individuals.

Is this concern shared, or do you believe it is something else (anecdotal only, caused by other factors, etc)? And if so, what do you believe is going on?

Thanks so much!

Hi, thanks for doing this!

Does MAPS (or perhaps yourselves as individuals), have an opinion on how the next wave of novel compounds will effect this industry and influence research?

For instance, the hundreds (thousands?) of new compounds that Sasha Shulgin created, tried, and were never synthesised again.

Similarly, the nascent field of AI-driven drug creation (using AI to find new compounds and simulating their action at various receptor sites. Is it possible that work in this space could disrupt the “classic” psychedelics which seem to have primary function on the 5HT2A receptor?